Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $420.00 Price Target at Royal Bank of Canada
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...
Nasdaq 100 logs worst quarter in three years - Here’s what’s driving the drop
The Nasdaq 100 (NDX) index just had the worst quarterly performance in the first quarter of 2025 in nearly three years. The tech-skewed index, which features heavyweights like Apple (AAPL) -11.3% YTD, ...
Vertex Pharmaceuticals price target raised to $420 from $408 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.
RBC Capital Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Vertex Pharmaceuticals (VRTX) Gets a Hold from Bernstein
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
How Peter Marks' FDA departure is impacting pharma, biotech stocks
The abrupt resignation announcement that came late on Friday, March 28, from Peter Marks, who heads the U.S. FDA's Center for Biologics Evaluation and Research, has sent reverberations throughout the ...